Board Meeting on October 29, 2026 to Approve Q2 and H1 Results
Board meeting on Thursday, October 29, 2026.
By ScoutQuest · · 1 min read
- Board Meeting Date
- Thursday, October 29, 2026
- Results Period
- quarter and half year ended September 30, 2026
- Trading Window Closure
- closed from October 1, 2026, till 48 hours after results are made public
What the company has told the exchanges
A meeting of the Board of Directors is scheduled on Thursday, October 29, 2026. The main agenda item is to consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026. The Board will also take on record the Limited Review Report on those results.
Why this matters
- This is the quarterly results announcement timeline for the three months ended September 30, 2026.
- Results will be presented in two forms: standalone (the company on its own) and consolidated (the company along with its subsidiaries, if any).
- A Limited Review Report is the auditor's review of unaudited quarterly numbers, which is a standard step for listed companies.
Trading window
- The trading window for dealing in the company's securities by designated persons and their immediate relatives is closed from October 1, 2026.
- It will continue to remain closed till 48 hours after the results are made public on October 29, 2026.
- This is an insider-trading safeguard; it restricts share transactions by insiders around the results period.
What to keep in mind
- This intimation is a schedule notice, not the results themselves. It does not contain revenue, profit, margin or any other financial figure.
- Investors looking for the numbers will get them when the results for the quarter and half year ended September 30, 2026 are approved and published.
- Such notices are a routine part of listed-company reporting and mainly tell the market when to expect the numbers.
Also from RPG Life Sciences
RPG Life Sciences to hold Q2 FY27 results earnings call on October 30, 2026 at 5:00 PM IST
23 Oct 2026
RPG Life Sciences Ltd shareholder buys 0.23% stake, holding rises to 7.04%
28 Sep 2026
Subsidiary Board Approves Amalgamation of Actis Generics with RPG Active Pharma
26 Sep 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.